Daxor (NASDAQ:DXR – Get Free Report) released its earnings results on Monday. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.07), FiscalAI reports. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $2.80 million.
Daxor Stock Performance
Daxor stock opened at $10.79 on Wednesday. The business has a fifty day moving average of $10.40 and a two-hundred day moving average of $10.53. Daxor has a twelve month low of $8.56 and a twelve month high of $14.76.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy”.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. acquired a new stake in shares of Daxor Corporation (NASDAQ:DXR – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.34% of the company’s stock.
Daxor Company Profile
Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.
In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.
Recommended Stories
- Five stocks we like better than Daxor
- Dutch Bros Sell-Off Creates a Growth Opportunity
- NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
- Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
- Medtronic’s Stars Are Aligning for a Price Recovery
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
